Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 May 2021Website:
http://dayonebio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 21:22:23 GMTDividend
Analysts recommendations
Institutional Ownership
DAWN Latest News
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals' Third Quarter of 2024 Financial and Operating Results Conference Call.
Day One Biopharmaceuticals, Inc. (DAWN) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to loss of $0.54 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024.
When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.
Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).
Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to treat all BRAF-mutated pLGG patients, whereas Novartis' combo only addresses about 10% to 20% of that population. With tovorafenib's somewhat risky rolling NDA submission slated for October 2023 and ample cash for commercialization, the recent beneficial owner buying merited a look into this busted IPO.
What type of business is Day One Biopharmaceuticals?
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
What sector is Day One Biopharmaceuticals in?
Day One Biopharmaceuticals is in the Healthcare sector
What industry is Day One Biopharmaceuticals in?
Day One Biopharmaceuticals is in the Biotechnology industry
What country is Day One Biopharmaceuticals from?
Day One Biopharmaceuticals is headquartered in United States
When did Day One Biopharmaceuticals go public?
Day One Biopharmaceuticals initial public offering (IPO) was on 27 May 2021
What is Day One Biopharmaceuticals website?
https://dayonebio.com
Is Day One Biopharmaceuticals in the S&P 500?
No, Day One Biopharmaceuticals is not included in the S&P 500 index
Is Day One Biopharmaceuticals in the NASDAQ 100?
No, Day One Biopharmaceuticals is not included in the NASDAQ 100 index
Is Day One Biopharmaceuticals in the Dow Jones?
No, Day One Biopharmaceuticals is not included in the Dow Jones index
When was Day One Biopharmaceuticals the previous earnings report?
No data
When does Day One Biopharmaceuticals earnings report?
Next earnings report date is not announced yet